Advanced Search

 

Study ID Status Title Patient Level Data
101468/016 Completed A Single Blind Study to Investigate the Effect of Ropinirole at Steady State on Plasma Concentrations of Digoxin in Parkinsonian Patients.
101468/032 Completed Anti-Parkinson Efficacy of Ropinirole (SKF 101468) versus Placebo as Monotherapy in Parkinson's Disease
101468/043 Completed A Double-Blind, Bromocriptine Controlled, Multicenter Study of Ropinirole at a Flexible Oral Dose of 0.25–8.0mg Three Times Daily for Six Months in the Treatment of Parkinsonian Patients Not Optimally Controlled on L-Dopa
101468/044 Completed A Double-Blind, Placebo Controlled, Parallel Group Study of Oral Doses of Ropinirole for Six Months Treatment of Adjunct Therapy in Parkinsonian Patients Not Optimally Controlled on L-Dopa (DCI)
101468/044 and SKF-101468/054 Completed Population Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Relationship of Ropinirole in Parkinsonian Patients
101468/053 Completed A Double-blind, Bromocriptine Controlled, Multicentre Study of Ropinirole at a Flexible Oral Dose of 0.25-8 mg Three Times Daily for Three Years in the Treatment of Early Parkinsonian Patients Not Treated with L-dopa
101468/054 Completed A Double-blind, Placebo Controlled, Parallel Group Study of Oral Doses of Ropinirole for Six Months in the Treatment of Early Parkinsonian Patients Not Receiving Dopaminergic Therapy
101468/056 Completed A Double-blind, L-dopa Plus Benserazide Controlled, Multicentre Study of Ropinirole at a Flexible Oral Dose of 0.25 – 8 mg Three Times Daily for Five Years in the Treatment of Early Parkinsonian Patients Not Treated with L-Dopa.
101468/061 Completed An open, randomised three-way crossover study to investigate the relative and absolute bioavailability of ropinirole following domperidone pretreatment in healthy male volunteers.
101468/062 Completed An open study to assess the pharmacokinetic interaction at steady state following multiple oral dosing, between Ropinirole (2 MG TDS) and L-Dopa (100 MG BD) (+ Decarboxylase Inhibitor) in L-Dopa naïve (De Novo) patients with Parkinson’s disease.
101468/063 Completed A repeat dose, steady state study to determine the effect of food on the pharmacokinetics of Ropinirole in Parkinson patients.
101468/090 Completed Compassionate use continuation of double-blind medication from ropinirole phase II & III studies or compassionate administration of open-label ropinirole in the treatment of Parkinson's disease
101468/099 Completed An Open Study to Assess the Safety and Efficacy of Ropinirole at a Flexible Oral Dose of 0.25-8.0mg Three Times a Day for One Year in Parkinsonian Patients Not Optimally Controlled on L-Dopa
101468/101 Completed A study to investigate the effect of steady state oral theophylline on the pharmacokinetics of ropinirole at steady state and the effect of steady state ropinirole on the pharmacokinetics of a single intravenous dose of theophylline in Parkinsonian patients.
101468/102 Completed A study to investigate the effect of repeated oral doses of ciprofloxacin on steady state ropinirole pharmacokinetics in Parkinsonian patients.
101468/124 Completed Open, Bromocriptine controlled study of Ropinirole at a flexible oral dose of 0.25-3.0mg T.I.D. in the treatment of Parkinsonian patients not optimally controlled on L-Dopa (DCI)
101468/125 Completed A double-blind, multicentre, flexible dose, L-dopa controlled study of ropinirole to investigate A) neuroprotective effect as measured by 3D PET scanning, and B) ophthalmological safety, in patients with early Parkinson’s disease Study Listed on ClinicalStudyDataRequest.com
101468/127 Completed A Double-blind, Randomised, Bromocriptine-controlled Study of Ropinirole at a Flexible Oral Dose of 0.25-3.0mg Three Times Daily for 4 Months in the Treatment of Parkinsonian Patients (Hoehn and Yahr Stage II-IV) Not Optimally Controlled on L-dopa (DCI).
101468/161 Completed A single dose study to compare the pharmacokinetics of ropinirole from three new formulations with the standard rmarketed reference formulation in healthy male volunteers and to assess the influence of food and domperidone on one of the new formulations
101468/162 Completed A four-way cross-over, placebo- and standard formulation -controlled study to compare the single-dose pharmacokinetics of ropinirole from new formulations and from the standard formulation in healthy male and female volunteers
101468/163 Completed A double-blind, two-way cross-over, placebo-controlled single dose and repeat dose study to investigate the pharmacokinetics of ropinirole after single and multiple doses of a CR-formulation in healthy male and female subjects.
101468/164 Completed An open-label, randomised, two part study to investigate the relative bioavailability of Ropinirole new and standard, marketed formulations and the effect of food on the pharmacokinetics of Ropinirole new formulation in early stage Parkinson’s disease subjects Study Listed on ClinicalStudyDataRequest.com
101468/165 Completed An open-label, up-titration study to assess the dose proportionality of ropinirole controlled release (CR) and to demonstrate the bioequivalence of ropinirole CR (1 x 8 mg) compared to the ropinirole CR (4 x 2 mg) in Parkinson's Disease patients not receiving other dopaminergic therapies. Study Listed on ClinicalStudyDataRequest.com
101468/166 Completed A Phase II, randomised, double-blind, active-controlled, dose-escalation study to determine the maximum well-tolerated starting dose of a new formulation of ropinirole in Parkinson's Disease patients not receiving other dopaminergic therapies Study Listed on ClinicalStudyDataRequest.com
101468/167 Completed A Phase II, randomized, double-blind, active-controlled study to determine the optimal initial titration regimen of a new formulation of ropinirole in Parkinson's disease subjects not receiving other dopaminergic therapies.

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.